Long-term outcomes after endoscopic treatment for Barrett's neoplasia with radiofrequency ablation ± endoscopic resection: results from the national Dutch database in a 10-year period.


Journal

Gut
ISSN: 1468-3288
Titre abrégé: Gut
Pays: England
ID NLM: 2985108R

Informations de publication

Date de publication:
02 2022
Historique:
received: 15 09 2020
revised: 02 03 2021
accepted: 08 03 2021
pubmed: 24 3 2021
medline: 9 3 2022
entrez: 23 3 2021
Statut: ppublish

Résumé

Radiofrequency ablation (RFA)±endoscopic resection (ER) is the preferred treatment for early neoplasia in Barrett's oesophagus (BE). We aimed to report short-term and long-term outcomes for all 1384 patients treated in the Netherlands (NL) from 2008 to 2018, with uniform treatment and follow-up (FU) in a centralised setting. Endoscopic therapy for early BE neoplasia in NL is centralised in nine expert centres with specifically trained endoscopists and pathologists that adhere to a joint protocol. Prospectively collected data are registered in a uniform database. Patients with low/high-grade dysplasia or low-risk cancer, were treated by ER of visible lesions followed by trimonthly RFA sessions of any residual BE until complete eradication of BE (CE-BE). Patients with ER alone were not included. After ER (62% of cases; 43% low-risk cancers) and median 1 circumferential and 2 focal RFA (p25-p75 0-1; 1-2) per patient, CE-BE was achieved in 94% (1270/1348). Adverse events occurred in 21% (268/1386), most commonly oesophageal stenosis (15%), all were managed endoscopically. A total of 1154 patients with CE-BE were analysed for long-term outcomes. During median 43 months (22-69) and 4 endoscopies (1-5), 38 patients developed dysplastic recurrence (3%, annual recurrence risk 1%), all were detected as endoscopically visible abnormalities. Random biopsies from a normal appearing cardia showed intestinal metaplasia (IM) in 14% and neoplasia in 0%. A finding of IM in the cardia was reproduced during further FU in only 33%, none progressed to neoplasia. Frequent FU visits in the first year of FU were not associated with recurrence risk. In a setting of centralised care, RFA±ER is effective for eradication of Barrett's related neoplasia and has remarkably low rates of dysplastic recurrence. Our data support more lenient FU intervals, with emphasis on careful endoscopic inspection. Random biopsies from neosquamous epithelium and cardia are of questionable value. NL7039.

Identifiants

pubmed: 33753417
pii: gutjnl-2020-322615
doi: 10.1136/gutjnl-2020-322615
pmc: PMC8762001
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

265-276

Investigateurs

A Karrenbeld (A)
A Ooms (A)
C Huysentruyt (C)
F Ten Kate (F)
F Moll (F)
G Kats-Ugurlu (G)
I van Lijnschoten (I)
J van de Laan (J)
J Offerhaus (J)
K Biermann (K)
K Seldenrijk (K)
L Brosens (L)
S Meijer (S)
M Doukas (M)
E Overdevest (E)
R Houwen (R)
A Kumçu (A)
M van Riswijk (M)
M W Chan (MW)
C Kroeze (C)
M Siim (M)
E Verheij (E)
S der Graaf (S)
S Nedjat (S)

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: SvM, EN, AH, AB, AA, BES, EJS, WC, ADK, SEMvdV, PJFdJ, TJT, WBN, FTMP, JW, MHMGH, REP declared to have no disclosures relevant to this manuscript. BLAMW received financial support for IRB-approved research from C2Therapeutics/Pentax Medical. JJGHMB received financial support for IRB-approved research from C2Therapeutics/Pentax Medical, Medtronic, and Aqua Medical.

Références

Gastroenterology. 2013 Jul;145(1):96-104
pubmed: 23542068
Clin Gastroenterol Hepatol. 2014 Nov;12(11):1840-7.e1
pubmed: 24815329
Gastrointest Endosc. 2011 Jul;74(1):35-43
pubmed: 21704807
Gastroenterology. 2018 Aug;155(2):316-326.e6
pubmed: 29655833
United European Gastroenterol J. 2019 May;7(4):538-547
pubmed: 31065371
Gastrointest Endosc. 2016 Jul;84(1):29-36
pubmed: 26769410
Am J Gastroenterol. 2011 Aug;106(8):1447-55; quiz 1456
pubmed: 21483461
Gastroenterology. 2019 Apr;156(5):1299-1308.e3
pubmed: 30610858
N Engl J Med. 2009 May 28;360(22):2277-88
pubmed: 19474425
Gastrointest Endosc. 2019 Apr;89(4):759-768
pubmed: 30447215
Gastrointest Endosc. 2011 Feb;73(2):195-203
pubmed: 21168835
Gastroenterology. 1999 Feb;116(2):277-85
pubmed: 9922307
Lancet. 1994 Dec 3;344(8936):1533-6
pubmed: 7983953
United European Gastroenterol J. 2019 Aug;7(7):889-896
pubmed: 31428413
Endoscopy. 2010 Oct;42(10):781-9
pubmed: 20857372
Dig Liver Dis. 2001 May;33(4):316-21
pubmed: 11432508
Gastrointest Endosc. 2020 Aug;92(2):259-268.e2
pubmed: 32240684
Am J Gastroenterol. 1999 Jan;94(1):98-103
pubmed: 9934738
J Gastrointest Surg. 2021 Jan;25(1):67-76
pubmed: 33140322
Gastrointest Endosc. 2011 Apr;73(4):682-90
pubmed: 21292262
Lancet Gastroenterol Hepatol. 2018 Aug;3(8):566-574
pubmed: 29934224
United European Gastroenterol J. 2018 Jul;6(6):830-837
pubmed: 30023060
Gut. 2019 Aug;68(8):1379-1385
pubmed: 30635408
Eur J Gastroenterol Hepatol. 1999 Nov;11(11):1265-70
pubmed: 10563538
Gastrointest Endosc. 2020 Sep;92(3):569-574
pubmed: 32217112
Am J Gastroenterol. 2009 Feb;104(2):502-13
pubmed: 19174812
Am J Gastroenterol. 2010 Jul;105(7):1523-30
pubmed: 20461069
Endoscopy. 2013 Jul;45(7):516-25
pubmed: 23580412
Gastroenterology. 2017 Apr;152(5):993-1001.e1
pubmed: 28012849
Gut. 2015 May;64(5):700-6
pubmed: 25034523
Gastrointest Endosc. 2017 Mar;85(3):482-495.e4
pubmed: 27670227
Gastrointest Endosc. 2019 Sep;90(3):415-423
pubmed: 31108093
Gut. 2016 Apr;65(4):555-62
pubmed: 25731874
Endoscopy. 2015 Nov;47(11):980-7
pubmed: 26126159
Endoscopy. 2017 Feb;49(2):191-198
pubmed: 28122386
JAMA. 2014 Mar 26;311(12):1209-17
pubmed: 24668102
Gastrointest Endosc. 2021 Jun;93(6):1250-1257.e3
pubmed: 33144238
Endoscopy. 2019 Apr;51(4):317-325
pubmed: 30360011
Endoscopy. 2013 Nov;45(11):876-82
pubmed: 24165812
Endoscopy. 2015 Jul;47(7):592-7
pubmed: 25675174
Endoscopy. 2014 Feb;46(2):105-9
pubmed: 24285123
Gastroenterology. 2020 Feb;158(3):760-769
pubmed: 31730766
Endoscopy. 2010 Apr;42(4):272-8
pubmed: 20146164

Auteurs

Sanne van Munster (S)

Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, The Netherlands.
Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, The Netherlands.

Esther Nieuwenhuis (E)

Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, The Netherlands.

Bas L A M Weusten (BLAM)

Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, The Netherlands.
Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

Lorenza Alvarez Herrero (L)

Gastroenterology and Hepatology, Sint Antonius Hospital, Nieuwegein, The Netherlands.

Auke Bogte (A)

Gastroenterology and Hepatology, University Medical Center Utrecht, Utrecht, The Netherlands.

Alaa Alkhalaf (A)

Gastroenterology and Hepatology, Isala Klinieken, Zwolle, Overijssel, The Netherlands.

B E Schenk (BE)

Gastroenterology and Hepatology, Isala Klinieken, Zwolle, Overijssel, The Netherlands.

Erik J Schoon (EJ)

Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

Wouter Curvers (W)

Department of Gastroenterology and Hepatology, Catharina Hospital Eindhoven, Eindhoven, The Netherlands.

Arjun D Koch (AD)

Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Steffi Elisabeth Maria van de Ven (SEM)

Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Pieter Jan Floris de Jonge (PJF)

Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands.

Tjon J Tang (TJ)

Department of Gastroenterology and Hepatology, IJsselland Ziekenhuis, Capelle aan den IJssel, Zuid-Holland, The Netherlands.

Wouter B Nagengast (WB)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Frans T M Peters (FTM)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Jessie Westerhof (J)

Department of Gastroenterology and Hepatology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.

Martin H M G Houben (MHMG)

Gastroenterology and Hepatology, Haga Hospital, Den Haag, Zuid-Holland, The Netherlands.

Jacques Jghm Bergman (JJ)

Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, The Netherlands j.j.bergman@amc.nl.

Roos E Pouw (RE)

Gastroenterology and Hepatology, Amsterdam UMC Locatie AMC, Amsterdam, North Holland, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH